All articles tagged with #isomorphic labs
Google DeepMind's affiliate, Isomorphic Labs, is preparing to begin human trials of AI-designed drugs, aiming to revolutionize drug development by increasing success rates and reducing costs, leveraging breakthroughs like AlphaFold for protein modeling.
Alphabet's Isomorphic Labs unit has announced research collaborations with Eli Lilly and Novartis to focus on small-molecule treatments and multiple targets using artificial intelligence for drug discovery, receiving upfront cash and possible milestone payments from both companies. Eli Lilly and Isomorphic Labs will collaborate on small molecule therapeutics for multiple targets, while the Novartis-Isomorphic collaboration will focus on finding small molecule therapeutics vs. three targets. Stocks for Eli Lilly and Novartis saw increases, while Alphabet's stock experienced a decline.
Isomorphic Labs, a drug discovery spin-out of DeepMind, has partnered with Eli Lilly and Novartis to use AI for drug discovery, with deals totaling $3 billion. Isomorphic will receive upfront payments and potential milestone-based incentives. The company utilizes DeepMind's AlphaFold 2 AI technology to predict protein structures, aiding in drug design. While not perfect, AlphaFold has shown promise in designing potential drugs for diseases like liver cancer and is being applied to neglected diseases. Isomorphic is under pressure to turn a profit after recording a loss in 2021.